Posted by Michael Wonder on 21 Aug 2020
BioMarin submits new drug application to U.S. FDA for vosoritide to treat children with achondroplasia
20 August 2020 - Potential first treatment for achondroplasia in the United States.
BioMarin Pharmaceutical today announced that it has submitted a new drug application to the U.S. FDA for vosoritide, an investigational, once daily injection analog of C-type natriuretic peptide for children with achondroplasia, the most common form of disproportionate short stature in humans.
BioMarin recently announced that the EMA validated the company's marketing authorisation application for vosoritide on 13 August 2020.
